Description
Risedronate is a bisphosphonate that exhibits anti-osteoporotic, anti-resorptive, anti-parasitic, and antimalarial activities. Risedronate inhibits bone marrow adipogenesis, decreases activity of mTORC1, and suppresses activation of NF-κB in vitro. In animal models, risedronate induces apoptosis in osteoclasts, upregulates expression of Bim, increases bone mineral density, and inhibits bone resorption. Additionally, risedronate inhibits Plasmodium survival in vivo by inhibiting transfer of farnesyl pyrophosphate.
References
Lems WF, den Heijer M. Established and forthcoming drugs for the treatment of osteoporosis. Neth J Med. 2013 May;71(4):188-93. PMID: 23723112.
Jin J, Wang L, Wang XK, et al. Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation. J Surg Res. 2013 Mar;180(1):e21-9. PMID: 22487394.
Matsumoto T, Nagase Y, Iwasawa M, et al. Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: role of the Akt pathway and the ERK/Bim axis. Arthritis Rheum. 2011 Dec;63(12):3908-17. PMID: 21898348.
Jordão FM, Saito AY, Miguel DC, et al. In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob Agents Chemother. 2011 May;55(5):2026-31. PMID: 21357292.
